Drugs / MK-8353
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03745989 | Feb 2019 → Mar 2021 | cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02972034 | Jan 2017 → Dec 2022 | colorectal cancer | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01358331 | Nov 2011 → May 2014 | soft tissue neoplasm | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8353 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02972034 ↗ |
| Known as | SCH 900353 | “A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of MK-8353 (Formerly SCH 900353) in Subjects With Advanced Solid Tumors (Protocol No. 001 (Formerly P06203))” NCT01358331 ↗ |
| Action | Inhibit | “Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.” PMID 29467321 ↗ Feb 2018 |
| Modality | Small molecule | “MK-8353 (small molecule inhibitor of extracellular signal-regulated kinase 1/2)” PMID 37040046 ↗ Apr 2023 |
| Route | Oral | “MK-8353 was administered in 100- to 800-mg dose cohorts orally twice daily.” PMID 29467321 ↗ Feb 2018 |
| Target | MAPK1 | “MAP kinase ERK2 inhibitor” CHEMBL4213970 ↗ |
| Target | MAPK3 | “MAP kinase ERK1 inhibitor” CHEMBL4213970 ↗ |